skip to main content
Idioma:
Mostrar Somente
Refinado por: tipo de recurso: Outros remover
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Entrevista a Eva Alterman Blay e Alice Beatriz da Silva Gordo Lang. [Entrevista]
Entrevista a Eva Alterman Blay e Alice Beatriz da Silva Gordo Lang. [Entrevista]
Material Type:
Outros 		Adicionar ao Meu Espaço

Entrevista a Eva Alterman Blay e Alice Beatriz da Silva Gordo Lang. [Entrevista]

Eva Alterman Blay Alice Beatriz da Silva Gordo Lang

Souza, Gilda de Mello e A palavra afiada Rio de Janeiro: Ouro sobre Azul, 2014

Rio de Janeiro Ouro sobre Azul 2014

Acesso online. A biblioteca também possui exemplares impressos.

2
TIME UNTIL DEFINITIVE DETERIORATION (TUDD) IN PATIENT REPORTED OUTCOMES (PROS) IN A PHASE 3 TRIAL FOR RIPRETINIB IN 4L PATIENTS WITH GASTROINTESTINAL STROMAL TUMOUR (GIST)
TIME UNTIL DEFINITIVE DETERIORATION (TUDD) IN PATIENT REPORTED OUTCOMES (PROS) IN A PHASE 3 TRIAL FOR RIPRETINIB IN 4L PATIENTS WITH GASTROINTESTINAL STROMAL TUMOUR (GIST)
Material Type:
Outros 		Adicionar ao Meu Espaço

TIME UNTIL DEFINITIVE DETERIORATION (TUDD) IN PATIENT REPORTED OUTCOMES (PROS) IN A PHASE 3 TRIAL FOR RIPRETINIB IN 4L PATIENTS WITH GASTROINTESTINAL STROMAL TUMOUR (GIST)

Becker, C ; Harrow, B ; Heinrich, M.C ; Schoffski, P ; Serrano, C ; Vincenzi, B ; Blay, J.Y

VALUE IN HEALTH, 2022, Vol.25 (1), p.S227-S227

ELSEVIER SCIENCE INC

Texto completo disponível

Citações Citado por
3
INTRIGUE: a randomized, open-label, phase 3 study evaluating the efficacy and safety of ripretinib versus sunitinib in patients with advanced gastrointestinal stromal tumors previously treated with imatinib
INTRIGUE: a randomized, open-label, phase 3 study evaluating the efficacy and safety of ripretinib versus sunitinib in patients with advanced gastrointestinal stromal tumors previously treated with imatinib
Material Type:
Outros 		Adicionar ao Meu Espaço

INTRIGUE: a randomized, open-label, phase 3 study evaluating the efficacy and safety of ripretinib versus sunitinib in patients with advanced gastrointestinal stromal tumors previously treated with imatinib

Bauer, S ; Jones, R.L ; Gelderblom, H ; George, S ; Schoeffski, P ; Von Mehren, M ; Zalcberg, J ; Kang, Y.K ; Razak, A.A ; Trent, J ; Attia, S ; Le Cesne, A ; Su, Y ; Meade, J ; Wang, T ; Sherman, M.L ; Ruiz-Soto, R ; Blay, J.Y ; Heinrich, M.C

ONCOLOGY RESEARCH AND TREATMENT, 2022, Vol.45 (SUPPL 2), p.263-263

KARGER

Texto completo disponível

Citações Citado por
4
Outcomes in patients with advanced gastrointestinal stromal tumor who did not have baseline ctDNA detected in the INTRIGUE study
Outcomes in patients with advanced gastrointestinal stromal tumor who did not have baseline ctDNA detected in the INTRIGUE study
Material Type:
Outros 		Adicionar ao Meu Espaço

Outcomes in patients with advanced gastrointestinal stromal tumor who did not have baseline ctDNA detected in the INTRIGUE study

Trent, Jonathan C ; Jones, Robin Lewis ; George, Suzanne ; Gelderblom, Hans ; Schoffski, Patrick ; von Mehren, Margaret ; Zalcberg, John Raymond ; Kang, Yoon-Koo ; Razak, Albiruni Ryan Abdul ; Attia, Steven ; Le Cesne, Axel ; Reichmann, William ; Sprott, Kam ; Achour, Haroun ; Sherman, Matthew L ; Ruiz-Soto, Rodrigo ; Blay, Jean-Yves ; Heinrich, Michael C ; Bauer, Sebastian

JOURNAL OF CLINICAL ONCOLOGY, 2023, Vol.41 (16)

LIPPINCOTT WILLIAMS & WILKINS

Texto completo disponível

Citações Citado por
5
Molecular analysis of archival clear cell sarcoma tissue samples from EORTC trial 90101 "CREATE" and correlation with response to crizotinib
Molecular analysis of archival clear cell sarcoma tissue samples from EORTC trial 90101 "CREATE" and correlation with response to crizotinib
Material Type:
Outros 		Adicionar ao Meu Espaço

Molecular analysis of archival clear cell sarcoma tissue samples from EORTC trial 90101 "CREATE" and correlation with response to crizotinib

Lee, Che-Jui ; Wozniak, Agnieszka ; Modave, Elodie ; Boeckx, Bram ; Stacchiotti, Silvia ; Rutkowski‬, Piotr ; Blay‬, Jean-Yves ; Debiec-Rychter, Maria ; Sciot, Raphael ; Schöffski, Patrick

2020

Texto completo disponível

Citações Citado por
6
Molecular analysis of archival inflammatory myofibroblastic tumor tissue samples from EORTC 90101 "CREATE" and correlation with response to crizotinib
Molecular analysis of archival inflammatory myofibroblastic tumor tissue samples from EORTC 90101 "CREATE" and correlation with response to crizotinib
Material Type:
Outros 		Adicionar ao Meu Espaço

Molecular analysis of archival inflammatory myofibroblastic tumor tissue samples from EORTC 90101 "CREATE" and correlation with response to crizotinib

Lee, Che-Jui ; Schöffski, Patrick ; Modave, Elodie ; Boeckx, Bram ; Lambrechts, Diether ; Sufliarsky, Jozef ; Gelderblom, Hans ; Blay, Jean-Yves ; Wozniak, Agnieszka

2019

Texto completo disponível

Citações Citado por
7
PEC-PRO: A new prognostic score from a series of 93 patients with localized perivascular epithelioid cell neoplasms (PEComas) treated with curative intent
PEC-PRO: A new prognostic score from a series of 93 patients with localized perivascular epithelioid cell neoplasms (PEComas) treated with curative intent
Material Type:
Outros 		Adicionar ao Meu Espaço

PEC-PRO: A new prognostic score from a series of 93 patients with localized perivascular epithelioid cell neoplasms (PEComas) treated with curative intent

Gantzer, Justine ; Toulmonde, Maud ; Severac, Francois ; Chamseddine, Ali N ; Charon-Barra, Celine ; Bourgmayer, Agathe ; Bertucci, Francois ; Ryckewaert, Thomas ; Valentin, Thibaud ; Firmin, Nelly ; Chaigneau, Loic ; Bompas, Emmanuelle ; Follana, Philippe ; Rioux-Leclercq, Nathalie ; Lemoal, Laurence Bozec ; Duffaud, Florence ; Schoffski, Patrick ; Blay, Jean-Yves ; Brahmi, Mehdi ; Malouf, Gabriel G

JOURNAL OF CLINICAL ONCOLOGY, 2022, Vol.40 (16)

LIPPINCOTT WILLIAMS & WILKINS

Texto completo disponível

Citações Citado por
8
Patient reported outcomes and tolerability in patients receiving ripretinib versus sunitinib after imatinib treatment in INTRIGUE: A phase 3 open-label study
Patient reported outcomes and tolerability in patients receiving ripretinib versus sunitinib after imatinib treatment in INTRIGUE: A phase 3 open-label study
Material Type:
Outros 		Adicionar ao Meu Espaço

Patient reported outcomes and tolerability in patients receiving ripretinib versus sunitinib after imatinib treatment in INTRIGUE: A phase 3 open-label study

Gelderblom, Hans ; Jones, Robin Lewis ; Blay, Jean-Yves ; George, Suzanne ; Schoffski, Patrick ; von Mehren, Margaret ; Zalcberg, John Raymond ; Kang, Yoon-Koo ; Razak, Albiruni Ryan Abdul ; Trent, Jonathan C ; Attia, Steven ; Le Cesne, Axel ; Harrow, Brooke ; Becker, Claus ; Wang, Tao ; Sherman, Matthew L ; Ruiz-Soto, Rodrigo ; Heinrich, Michael C ; Bauer, Sebastian

JOURNAL OF CLINICAL ONCOLOGY, 2022, Vol.40 (16)

LIPPINCOTT WILLIAMS & WILKINS

Texto completo disponível

Citações Citado por
9
A phase II, multicenter study of the EZH2 inhibitor tazemetostat in adults (INI1-negative tumors cohort) (NCT02601950)
A phase II, multicenter study of the EZH2 inhibitor tazemetostat in adults (INI1-negative tumors cohort) (NCT02601950)
Material Type:
Outros 		Adicionar ao Meu Espaço

A phase II, multicenter study of the EZH2 inhibitor tazemetostat in adults (INI1-negative tumors cohort) (NCT02601950)

Stacchiotti, S ; Blay, J.-Y ; Jones, R.L ; Demetri, G.D.D ; Mir, O ; Italiano, A ; Thomas, D ; Chen, T.W.-W ; Schoffski, P ; Gil, T ; Jahan, T ; Cote, G ; Ratan, R ; Attia, S ; Roche, M ; Daigle, S ; Sapir, I ; Clawson, A ; Gounder, M

ANNALS OF ONCOLOGY, 2018, Vol.29, p.580-580

OXFORD UNIV PRESS

Texto completo disponível

Citações Citado por
10
ACTIVITY AND SAFETY OF CRIZOTINIB IN PATIENTS WITH ADVANCED CLEAR CELL SARCOMA (CCSA) WITH MET ALTERATIONS. EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER PHASE 2 TRIAL 90101 "CREATE"
ACTIVITY AND SAFETY OF CRIZOTINIB IN PATIENTS WITH ADVANCED CLEAR CELL SARCOMA (CCSA) WITH MET ALTERATIONS. EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER PHASE 2 TRIAL 90101 "CREATE"
Material Type:
Outros 		Adicionar ao Meu Espaço

ACTIVITY AND SAFETY OF CRIZOTINIB IN PATIENTS WITH ADVANCED CLEAR CELL SARCOMA (CCSA) WITH MET ALTERATIONS. EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER PHASE 2 TRIAL 90101 "CREATE"

Schöffski, Patrick ; Wozniak, Agnieszka ; Stacchiotti, Silvia ; Rutkowski, Piotr ; Blay, Jean-Yves ; Lindner, Lars ; Strauss, Sandra ; Anthoney, Alan ; Duffaud, Florence ; Richter, Stephan ; Sciot, Raf ; Debiec-Rychter, Maria ; Marreaud, Sandrine ; Collette, Laurence ; Bauer, Sebastian

2018

Texto completo disponível

Citações Citado por

Personalize Seus Resultados

  1. Editar

Refine Search Results

Expandir Meus Resultados

  1.   

Mostrar Somente

  1. Disponível na Biblioteca (1)

Novas Pesquisas Sugeridas

Ignorar minha busca e procurar por tudo

Deste Autor:

  1. Lang, A
  2. Blay, E

Neste Assunto:

  1. Trabalho
  2. Mulheres (Condições Sociais)
  3. PROFESSORES DE ENSINO SUPERIOR (FORMAÇÃO PROFISSIONAL)
  4. Souza, Gilda de Mello e 1919-2005

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.